research use only

BDTX-1535 EGFR inhibitor

Name: BDTX-1535
Brand: Selleck Chemicals
SKU: E1478
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E1478

BDTX-1535 (EGFR-IN-76) is an orally available, highly potent, selective, and irreversible EGFR inhibitor that can penetrate the blood-brain barrier, with the potential to treat Glioblastoma or Non-Small Cell Lung Cancer.

Chemical Structure

Molecular Weight: 561.05

Jump to

Quality Control

Batch: E147801 DMSO]100 mg/mL]false]Ethanol]5 mg/mL]false]Water]Insoluble]false Purity: 99.02%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS
Datasheet

99.02

Related Targets	VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 c-Kit
Other EGFR Inhibitors	Sunvozertinib Icotinib Hydrochloride AG-490 AG-1478 Canertinib (CI-1033) Rociletinib (CO-1686) WZ4002 Genistein Poziotinib (NOV120101, HM781-36B) PD153035

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (178.23 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 5 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (8.91mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.500mg/ml (0.89mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	561.05	Formula	C₃₀H₃₀ClFN₆O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	2607829-38-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Mechanism of Action

Targets/IC₅₀/Ki	EGFR
References	[1] https://pubmed.ncbi.nlm.nih.gov/36255589/ [2] https://pubmed.ncbi.nlm.nih.gov/35805940/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06072586	Recruiting	High Grade Glioma	St. Joseph''s Hospital and Medical Center Phoenix\|Ivy Brain Tumor Center\|Barrow Neurological Institute	October 18 2023	Early Phase 1
NCT05256290	Recruiting	Non-Small Cell Lung Cancer\|Advanced Non-Small Cell Squamous Lung Cancer\|Metastatic Lung Non-Small Cell Carcinoma\|Metastatic Lung Cancer\|NSCLC\|Advanced Lung Carcinoma\|Epidermal Growth Factor Receptor C797S\|Epidermal Growth Factor Receptor G719X\|EGF-R Positive Non-Small Cell Lung Cancer\|EGFR-TKI Resistant Mutation	Black Diamond Therapeutics Inc.	March 31 2022	Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):